An Open Label Positron Emission Tomography (PET) Study Using 2-[18F]-F-A85380 to Determine alpha-4-beta-2 Neuronal Nicotinic Receptor Occupancy of AZD3480 [ispronicline] After Oral Administration to Healthy Male Subjects (Non Nicotine Users).

Trial Profile

An Open Label Positron Emission Tomography (PET) Study Using 2-[18F]-F-A85380 to Determine alpha-4-beta-2 Neuronal Nicotinic Receptor Occupancy of AZD3480 [ispronicline] After Oral Administration to Healthy Male Subjects (Non Nicotine Users).

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2010

At a glance

  • Drugs Ispronicline (Primary)
  • Indications Alzheimer's disease; Attention-deficit hyperactivity disorder; Memory disorders; Schizophrenia
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Dec 2010 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
    • 25 Sep 2008 Actual number of patients is 9, according to ClinicalTrials.gov record.
    • 25 Sep 2008 Status changed from recruiting to completed according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top